In June 2026, American medical AI firm OpenEvidence was ranked first in the life sciences sector on the Hurun Global Unicorn Index 2026, achieving a 12 billion dollar valuation. This milestone follows a 250 million dollar Series D financing round in January 2026 led by Thrive Capital and DST Global, which doubled the company valuation within three months. Founded in 2022 by Harvard-trained entrepreneur Daniel Nadler and Zachary Ziegler, OpenEvidence has rapidly emerged as a dominant force in clinical decision support by offering a specialized AI platform that functions as a secure, evidence-based medical search engine for physicians. Unlike general-purpose large language models prone to hallucination, OpenEvidence employs a retrieval-augmented generation architecture tailored for clinical use. When queried, the system scans thousands of peer-reviewed studies, clinical guidelines, and institutional repositories to generate citable answers. To address credibility concerns, the platform launched EvidenceGrade in July 2026, which automatically scores the clinical strength of cited literature using the GRADE framework. Strategic content partnerships with major institutions including the NEJM Group, JAMA Network, and the American Heart Association ensure access to high-quality, proprietary medical data. OpenEvidence growth trajectory has been fueled by a distinctive go-to-market strategy that circumvents traditional hospital procurement cycles. By offering the platform free to verified U.S. clinicians, the company transformed a B2B sales challenge into rapid consumer-grade adoption. As of July 2026, the platform serves approximately 915,000 certified medical professionals, with usage reaching 27 million clinical consultations in a single month. Query volumes have scaled from three million monthly in late 2024 to over 18 million, culminating in one million daily doctor-initiated searches by March 2026. This massive engaged user base has attracted pharmaceutical and medical device manufacturers seeking direct access to prescribers, generating a targeted digital advertising network that contributed to over 100 million in annual revenue by 2025. The platform is currently transitioning from individual physician tools to integrated clinical infrastructure. Major health systems including Sutter Health, Mount Sinai, and NewYork-Presbyterian have deployed OpenEvidence within Epic electronic health record environments, extending access to nurses and pharmacists. Despite clinical praise for its ability to accelerate evidence retrieval and support cross-specialty consultation, the platform faces ongoing scrutiny regarding diagnostic accuracy in complex or rare disease scenarios. Academic evaluations of its performance remain divided, reflecting varying evaluation methodologies and the inherent limitations of AI-generated clinical summaries. At a valuation exceeding one hundred times its current annual revenue, OpenEvidence must now demonstrate that enterprise EHR integration and sustained clinical trust can convert its user base into a stable, long-term revenue pipeline while navigating the rigorous safety standards of healthcare technology.